Clinical Trial Update: A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial evaluating the efficacy and safety of trastuzumab deruxtecan in patients with HER2-mutant non-small cell lung cancer; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: HER2-mutant Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-04